Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders' Equity

v2.4.0.6
Consolidated Statements of Shareholders' Equity (USD $)
In Thousands, except Share data
Total
USD ($)
Number of Common Shares (in thousands of U.S. dollars, except share amounts)
Common shares and Additional Paid-In Capital
USD ($)
Accumulated Other Comprehensive Income (Loss) (in thousands of U.S. dollars, except share amounts)
USD ($)
Comprehensive Loss (in thousands of U.S. dollars, except share amounts)
USD ($)
Accumulated deficit (in thousands of U.S. dollars, except share amounts)
USD ($)
Beginning balance at Dec. 31, 2008 $ 10,707   $ 56,076 $ 2,640 $ 0 $ (48,009)
Beginning balance, shares at Dec. 31, 2008   5,544,114        
Stock-based compensation expense 380   380      
Shares issued in July 2009 and October 2010 financing, shares   475,000        
Shares issued in July 2009 and October 2010 financing 9,304   9,304      
Shares issued in Teva stock purchase agreement, shares   267,531        
Shares issued in Teva stock purchase agreement 7,903   7,903      
Stock option exercises, shares   37,388        
Stock option exercises 141   141      
Loss for the period (5,476)       (5,476) (5,476)
Comprehensive loss for the period         (5,476)  
Ending balance at Dec. 31, 2009 22,959   73,804 2,640 0 (53,485)
Ending balance, shares at Dec. 31, 2009   6,324,033        
Stock-based compensation expense 642   642      
Shares issued in July 2009 and October 2010 financing, shares   3,174,602        
Shares issued in July 2009 and October 2010 financing 32,319   32,319      
Net unrealized loss on marketable securities (35)     (35) (35)  
Stock option exercises, shares   194,956        
Stock option exercises 824   824      
Loss for the period (12,584)       (12,584) (12,584)
Comprehensive loss for the period         (12,619)  
Ending balance at Dec. 31, 2010 44,125   107,589 2,605 0 (66,069)
Ending balance, shares at Dec. 31, 2010   9,693,591        
Stock-based compensation expense 1,188   1,188      
Shares issued in July 2009 and October 2010 financing 0          
Net unrealized loss on marketable securities (4)     (4) (4)  
Reverse prior year's net unrealized loss on marketable securities 35     35    
Stock option exercises, shares   56,228        
Stock option exercises 219   219      
Loss for the period (14,673)       (14,673) (14,673)
Comprehensive loss for the period         (14,677)  
Ending balance at Dec. 31, 2011 $ 30,890   $ 108,996 $ 2,636 $ 0 $ (80,742)
Ending balance, shares at Dec. 31, 2011   9,749,819